期刊
CELL BIOCHEMISTRY AND BIOPHYSICS
卷 71, 期 3, 页码 1405-1414出版社
HUMANA PRESS INC
DOI: 10.1007/s12013-014-0363-0
关键词
Carbon nanotubes; Breast cancer therapy; Paclitaxel; Targeted drug delivery; Human serum albumin
资金
- Canadian Institutes of Health Research (CIHR) [MOP 93641]
- Biomedical Engineering Department, McGill University
- FRQS (Fonds de recherche du Quebec-Sante) Doctoral award
- Natural Sciences and Engineering Research Council of Canada (NSERC)
Paclitaxel (PTX) is one of the most important drugs for breast cancer; however, the drug effects are limited by its systematic toxicity and poor water solubility. Nanoparticles have been applied for delivery of cancer drugs to overcome their limitations. Toward this goal, a novel single-walled carbon nanotube (SWNT)-based drug delivery system was developed by conjugation of human serum albumin (HSA) nanoparticles for loading of antitumor agent PTX. The nanosized macromolecular SWNT-drug carrier (SWNT-HSA) was characterized by TEM, UV-Vis-NIR spectrometry, and TGA. The SWNT-based drug carrier displayed high intracellular delivery efficiency (cell uptake rate of 80 %) in breast cancer MCF-7 cells, as examined by fluorescence-labeled drug carriers, suggesting the needle-shaped SWNT-HSA drug carrier was able to transport drugs across cell membrane despite its macromolecular structure. The drug loading on SWNT-based drug carrier was through high binding affinity of PTX to HSA proteins. The PTX formulated with SWNT-HSA showed greater growth inhibition activity in MCF-7 breast cancer cells than PTX formulated with HSA nanoparticle only (cell viability of 63 vs 70 % in 48 h and 53 vs 62 % in 72 h). The increased drug efficacy could be driven by SWNT-mediated cell internalization. These data suggest that the developed SWNT-based antitumor agent is functional and effective. However, more studies for in vivo drug delivery efficacy and other properties are needed before this delivery system can be fully realized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据